BO session on Generics Feedact from Egypt,
Description: BO session on Generics Feedact from Egypt, republic of korea and ukraine 7120XX Pitch deck title 2 Egypt No distinction between generic applications and non-generics Reference made to a product containing the same active ingredient,
Related Topics
Download Presentation
"BO session on Generics Feedact from Egypt," is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
slide1. BO session on Generics Feedact from Egypt, republic of korea and ukraine<br>
slide2. 7/1/20XX Pitch deck title 2 Egypt No distinction between generic applications and non-generics
Reference made to a product containing the same active ingredient, authorised by a stringent authority
Assessment is focused on Quality
BE is not required
Acceptable differences compared to reference product:
- different salts
The authorisation in Egypt may differ from that in the stringent authority – eg, different indication and species
Regulatory authorities would like to require BE but would require change to legislation
No data protection rules apply<br>
slide3. 7/1/20XX Pitch deck title 3 Republic of korea Generic product must be same type, have same specification and quantity of active ingredient as a reference product
Same dosage form, target animal(s), efficacy, dosage and withdrawal period
Initial assessment is focused on Quality specifications and manufacturing, including stability data
BE is required in those cases where there are differences compared to reference product and where Quality and manufacturing review indicate that absorption may not be same as for refence product
VICH GL52 is used but there is also local guidance
Generic applications for vaccines are possible where product is same type, concentration of active substance is same, dosage form is same and the same manufacturing site of the final bulk solution
Data protection: 4 to 6 years<br>
slide4. 7/1/20XX Pitch deck title 4 UKRAine Legislation is currently under revision. New legislation will be based on that of EU but…
Under a lot of pressure from industry to have a favourable interpretation of EU legislation – eg,
accept a reference product authorised in EU (Ukrainian authorities would not have access to dossier)
Role of competent authority - no scientific assessment by CA
Products are either full or Generics
For generics pharmaceutical equivalence is usually claimed
Where BE studies are conducted VICH GL is used. EU CVMP GL is also used
Data protection will be as in EU but currently there is none
Many applications for combination antimicrobial products<br>
slide5. 7/1/20XX Pitch deck title 5 UKRAine… Many applications for combination antimicrobial products not consistent with prudent use, but no legal basis to reject
Generics have an independent life once authorised
Reference product may be removed in Ukraine – how to update generic eg, if withdrawal period of reference product on market outside Ukraine changes
Responses:
Company are responsible for keeping product up to date (take account of new scientific data)
In some regions the regulator can require changes to authorisation<br>
slide6. 7/1/20XX Pitch deck title 6 General Need for residue studies (for food producing animals):
In USA and Japan – always
In EU – only for locally administered products
Australia – case by case (and specific WPs apply for export)
Labelling
Ukraine – same as reference product
Egypt – no specific requirements
ROK – no specific requirements<br>
slide7. 7/1/20XX Pitch deck title 7 General Extrapolation of BE to minor species:
In USA and EU (guidance) – only for minor species based on appropriate justifcation<br>
slide8. THANK YOU 7/1/20XX Pitch deck title 8<br>
slide2. 7/1/20XX Pitch deck title 2 Egypt No distinction between generic applications and non-generics
Reference made to a product containing the same active ingredient, authorised by a stringent authority
Assessment is focused on Quality
BE is not required
Acceptable differences compared to reference product:
- different salts
The authorisation in Egypt may differ from that in the stringent authority – eg, different indication and species
Regulatory authorities would like to require BE but would require change to legislation
No data protection rules apply<br>
slide3. 7/1/20XX Pitch deck title 3 Republic of korea Generic product must be same type, have same specification and quantity of active ingredient as a reference product
Same dosage form, target animal(s), efficacy, dosage and withdrawal period
Initial assessment is focused on Quality specifications and manufacturing, including stability data
BE is required in those cases where there are differences compared to reference product and where Quality and manufacturing review indicate that absorption may not be same as for refence product
VICH GL52 is used but there is also local guidance
Generic applications for vaccines are possible where product is same type, concentration of active substance is same, dosage form is same and the same manufacturing site of the final bulk solution
Data protection: 4 to 6 years<br>
slide4. 7/1/20XX Pitch deck title 4 UKRAine Legislation is currently under revision. New legislation will be based on that of EU but…
Under a lot of pressure from industry to have a favourable interpretation of EU legislation – eg,
accept a reference product authorised in EU (Ukrainian authorities would not have access to dossier)
Role of competent authority - no scientific assessment by CA
Products are either full or Generics
For generics pharmaceutical equivalence is usually claimed
Where BE studies are conducted VICH GL is used. EU CVMP GL is also used
Data protection will be as in EU but currently there is none
Many applications for combination antimicrobial products<br>
slide5. 7/1/20XX Pitch deck title 5 UKRAine… Many applications for combination antimicrobial products not consistent with prudent use, but no legal basis to reject
Generics have an independent life once authorised
Reference product may be removed in Ukraine – how to update generic eg, if withdrawal period of reference product on market outside Ukraine changes
Responses:
Company are responsible for keeping product up to date (take account of new scientific data)
In some regions the regulator can require changes to authorisation<br>
slide6. 7/1/20XX Pitch deck title 6 General Need for residue studies (for food producing animals):
In USA and Japan – always
In EU – only for locally administered products
Australia – case by case (and specific WPs apply for export)
Labelling
Ukraine – same as reference product
Egypt – no specific requirements
ROK – no specific requirements<br>
slide7. 7/1/20XX Pitch deck title 7 General Extrapolation of BE to minor species:
In USA and EU (guidance) – only for minor species based on appropriate justifcation<br>
slide8. THANK YOU 7/1/20XX Pitch deck title 8<br>